曝光后换马甲重来，不容问题氨糖狡兔三窟

Core Viewpoint - The article highlights the ongoing issue of false advertising in the healthcare sector, particularly regarding glucosamine products and lutein, which claim to provide unverified health benefits [4][5][6]. Group 1: False Advertising Practices - Some companies continue to promote glucosamine products with misleading claims about joint health and cartilage repair, despite previous exposure and regulatory actions [4][5]. - Lutein brands are using indirect methods to suggest their products can prevent myopia, without making direct claims [5]. Group 2: Regulatory Challenges - The imbalance between the low cost of violations and the high profit margins from misleading advertising allows companies to continue these practices with minimal consequences [6]. - Current regulatory measures are reactive rather than proactive, lacking real-time monitoring of marketing content across different platforms [6]. Group 3: Consumer Vulnerability - Consumers often lack the necessary knowledge to discern the actual efficacy of glucosamine and lutein, making them susceptible to misleading claims [6]. - Misleading marketing tactics, such as false endorsements from "overseas brands" or "doctor recommendations," exploit consumer ignorance [6]. Group 4: Recommendations for Improvement - A systematic and long-term regulatory mechanism is needed, including enhanced pre-approval responsibilities for e-commerce platforms to monitor health product advertising [7]. - Increasing penalties for companies that continue to engage in misleading marketing practices is essential to deter such behavior [7]. - Public education on the actual benefits and limitations of glucosamine and lutein should be strengthened to reduce the space for false advertising [7].